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Background: Antimicrobial resistance (AMR) in Enterobacterales is a global health threat. Capacity for individ-
ual-level surveillance remains limited in many countries, whilst population-level surveillance approaches
could inform empiric antibiotic treatment guidelines.
Methods: In this exploratory study, a novel approach to population-level prediction of AMR in Entero-
bacterales clinical isolates using metagenomic (Illumina) profiling of pooled DNA extracts from human
faecal samples was developed and tested. Taxonomic and AMR gene profiles were used to derive tax-
onomy-adjusted population-level AMR metrics. Bayesian modelling, and model comparison based on
cross-validation, were used to evaluate the capacity of each metric to predict the number of resistant
Enterobacterales invasive infections at a population-level, using available bloodstream/cerebrospinal
fluid infection data.
Findings: Population metagenomes comprised samples from 177, 157, and 156 individuals in Kenya, the
UK, and Cambodia, respectively, collected between September 2014 and April 2016. Clinical data from
independent populations included 910, 3356 and 197 bacterial isolates from blood/cerebrospinal fluid
infections in Kenya, the UK and Cambodia, respectively (samples collected between January 2010 and
May 2017). Enterobacterales were common colonisers and pathogens, and faecal taxonomic/AMR gene
distributions and proportions of antimicrobial-resistant Enterobacterales infections differed by setting.
A model including terms reflecting the metagenomic abundance of the commonest clinical Enterobac-
terales species, and of AMR genes known to either increase the minimum inhibitory concentration
(MIC) or confer clinically-relevant resistance, had a higher predictive performance in determining pop-
ulation-level resistance in clinical Enterobacterales isolates compared to models considering only AMR
gene information, only taxonomic information, or an intercept-only baseline model (difference in
expected log predictive density compared to best model, estimated using leave-one-out cross-valida-
tion: intercept-only model = -223 [95% credible interval (CI): -330,-116]; model considering only AMR
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2 O.T. Auguet et al. / EClinicalMedicine 36 (2021) 100910Interpretation: Whilst our findings are exploratory and require validation, intermittent metagenomics of
pooled samples could represent an effective approach for AMR surveillance and to predict population-level
AMR in clinical isolates, complementary to ongoing development of laboratory infrastructures processing
individual samples.
© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license




amples, could be of
(i) enabling surveil-
i) informing empiric
the impact of inter-
the terms “metage-
“infection” (01/Jan/









ent age groups (neo-
d AMR metrics com-
profiles from pools,
formance when con-
odel for their ability
e of AMR in clinical
etrics.
ry novel approach is








Antimicrobial resistance (AMR) is a global health emergency [1],
particularly in resource-limited settings, where effective microbio-
logical services and antibiotics may be unavailable [2]. Surveillance is
key to mitigating the effects of AMR by monitoring trends, informing
empiric treatment guidelines, identifying emerging threats, and eval-
uating the impact of interventions. There has been significant invest-
ment in individual/patient-level surveillance, and an attempt to
promote standardised collection, analysis and sharing of global AMRdata, capturing both clinical and microbiological information [3].
However, limitations of these approaches include developing and
sustaining robust capacity in regions where AMR is most prevalent,
and in obtaining systematic data even from countries with adequate
infrastructure. Population-level surveillance strategies complemen-
tary to the implementation of such individual-level approaches
would be of benefit.
Colonisation with specific species and/or drug-resistant organ-
isms, such as nasal colonisation with Staphylococcus aureus [4], or
rectal colonisation with carbapenemase-producing Enterobacterales,
[5] is associated with infection risk. Metagenomic approaches are less
biased than culture-based approaches, and metagenomic AMR gene
abundances and taxonomic distributions have been used as corre-
lates for national antibiotic exposures and AMRmonitoring in sewage
[610]. However, to our knowledge, no study has used taxonomic
and AMR gene profiles in pooled metagenomes to directly estimate
AMR prevalence amongst clinical isolates in populations in the same
setting. This approach would enable intermittent, strategic sampling
of a population subset to estimate the burden of AMR in clinical iso-
lates. Most colonisation sites are easy-to-sample and sampling is
well-tolerated (e.g. faeces/rectal swabs).
The concept of a metagenomic taxonomy-adjusted AMR metric or
“resistance potential” has been described previously [6,11] as the
average metagenome fraction encoding AMR genes for a particular
antibiotic or class, across all bacterial taxa in a sample that can poten-
tially carry such AMR genes, based on assumed taxonomic ranges for
respective AMR gene families. As a proof-of-principle study we
sequenced pooled faecal samples from a population subset of >100
individuals in three disparate geographic settings with varying Enter-
obacterales AMR prevalence and infection rates, namely Cambodia,
Kenya and the United Kingdom (UK), creating three pooled popula-
tion metagenomes. We developed a set of Bayesian generalised linear
models - each using different combinations of taxonomy and AMR
metagenomic metrics derived from these metagenomes - to predict
AMR prevalence at a population-level in clinical Enterobacterales iso-
lates in each setting. Bayesian model comparison was then used to
determine the value of metagenomic taxonomy-adjusted AMR met-
rics for out-of-sample predictive accuracy in determining the preva-
lence of AMR in clinical Enterobacterales isolates .2. Methods
2.1. Samples and settings
Faecal material collected after 2014 at pre-admission clinics or on
admission to hospital from three age-groups and settings was stud-
ied, namely: children 159 months in Kilifi, Kenya; newborns in
Siem Reap, Cambodia; and adults 18 years in London, UK (appendix
p2). Rectal swabs and faecal samples have both been used as
approaches for intestinal metagenomics [12,13], and give comparable
results [14].
For each study site, microbiology metadata for blood/cerebrospi-
nal fluid samples (as most robustly representative of truly invasive
infections) collected within 072 h of admission to hospital (i.e. com-
munity-associated) from 01/Jan/201031/May/2017 were collated.
Each site has a microbiology laboratory participating in external qual-
ity assurance schemes and accreditation processes (appendix p2).
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accordance with international guidelines (appendix p2). Collated
metadata included bacterial species and antibiotic susceptibility test
(AST) results, specimen type, and basic patient details to validate
aggregate-level stratification by age. Infection metadata were col-
lated for individuals < 90 days of age in Cambodia,  60 months of
age in Kenya and  18 years of age in the UK (appendix pp2-3).
2.2. DNA extraction
DNA was extracted from each sample using the MoBio PowerSoil
DNA isolation kit (Qiagen, Hilden, Germany), as per the manufacturer’s
instructions with optimisation steps to achieve sufficient DNA yields for
sequencing (ideally 300 ng DNA/34ul, with a view to obtaining
20Gbp (Giga base pairs) of data per sample; appendix pp4-8).
2.3. Sample pooling
DNA extracts were stored at 20 °C prior to pooling and sequenc-
ing. For each study setting, we created a “population pool”, which
consisted of the pooling of equimolar concentrations of all extracts
from that setting with 1 ng DNA/ml. To validate our pooling
approach (see appendix pp11, 18-19), we also created one smaller
pool for each setting, a “30-sample pool”, which consisted of equimo-
lar concentrations of 30 randomly selected extracts with 300 ng
DNA/34ml. An aliquot from each extract included in the 30-sample
pools was also sequenced individually for the validation (i.e.
sequenced extracts from 90 individuals in total). An aliquot from all
extracts sequenced individually and included in the 30-sample pools
was also included in the population pools.
2.4. Metagenomic sequencing
Sequencing of all faecal sample DNA extracts (pools and individual
extracts) was performed using the HiSeq 4000 Illumina platform,
generating 150 bp paired-end reads (i.e. 96 metagenomes [n = 90
individual metagenomes, n = 3 30-sample pools, n = 3 population
pools]; appendix p9).
2.5. Sequence data processing
Taxonomic abundance of bacterial species and AMR genes at indi-
vidual and pooled sample levels was determined using a published
bioinformatics pipeline, ResPipe [15]. This pipeline incorporates
established approaches to taxonomic profiling, namely Kraken2 [16]
and Bracken [17], and an adapted approach to quantifying AMR gene
markers present in a metagenome by mapping sequences against the
Comprehensive Antibiotic Resistance Database [18,19] (CARD,
v.3.0.3) (for method details, see appendix p9). All AMR genes identi-
fied in any of the samples were included in the analysis. Since
ResPipe reports the number of sequences that mapped to each AMR,
in order to remove reference gene length bias, the AMR gene profiles
- i.e. the numbers of sequences mapping to each AMR gene - were
corrected using the following formula: corrected gene count
(CGC) = (specific read count x average read length) / (AMR gene
length x specific lateral coverage) where (1) specific read count is the
number of sequences mapping exclusively to the reference AMR
gene; (2) specific lateral coverage is the proportion of the AMR gene
covered by sequences mapping exclusively to the gene; (3) AMR gene
length is the length of the gene the sequence is mapped to; and (4)
average read length is average length of reads that mapped to the
AMR gene.
The CARD database classifies each reference AMR gene by its asso-
ciation with phenotypic resistance. To be in CARD, an AMR gene must
be described in a peer-reviewed scientific publication, have its DNA
sequence available in GenBank, and include experimental evidenceof elevated minimum inhibitory concentration (MIC) over controls.
[19] We used these data to map and aggregate counts of AMR genes/
variants associated with resistance to specific antibiotics. We ranked
the AMR genes/variants into two categories, reflecting to some extent
the public health risks posed [20]. The first category, AMRDEF,
included only AMR determinants with the CARD “Confers_Resistan-
ce_to_Antibiotic” relationship ontology term, whereby the gene is
known to confer or contribute to clinically relevant resistance to a
specific antibiotic [19]. The second category, AMRALL, contained cor-
rected counts of all AMR determinants with clear experimental evi-
dence of increasing the MIC, including those associated with
clinically relevant resistance (as for AMRDEF), but also those without
the definitive “Confers_Resistance_to_Antibiotic” relationship ontology
term. In this study we have used “antimicrobial resistance (AMR)
gene” to define any relevant marker of resistance, including genes
that confer resistance by mutation (but can have a susceptible wild
type), and genes that confer resistance through presence/absence.
2.6. Taxonomy-Adjusted antimicrobial resistance (AMR) metrics
We developed AMR metrics and taxonomy metrics from pooled
metagenomes (i.e. “population pools”) to predict the number of resis-
tant isolates causing infection in each setting. Resistance metrics
(RCGC) aim to summarise information about relative abundance of
genes conferring resistance for a given antibiotic. These are given
through the sum of corrected gene counts (CGCs) of AMR gene var-
iants associated with resistance to a given antibiotic, j (RCGCj), divided
by the total CGC of all AMR genes in the pool. We considered two
possibilities. First, RCGC_DEF considered only AMR determinants
known to definitively confer clinically relevant resistance (using
AMRDEF, as defined above). Second, RCGC_ALL was calculated for AMR
determinants with clear experimental evidence of increasing the MIC
(using AMRALL). Taxonomic metrics (RTax) aim to represent relative
taxonomic abundance, and were given through the estimated abun-
dance of a clinically relevant bacterial grouping divided by the total
estimated abundance of bacterial taxa in the pool. Three bacterial
groupings were evaluated: (i) the entire Enterobacterales order
(RTax_E); (ii) species in the Enterobacteriaceae family only (RTax_e); and
(iii) the grouping of the four most common and clinically relevant
bacterial genera/species within the Enterobacteriaceae family across
study sites (namely Escherichia coli, Klebsiella pneumoniae, Salmonella
spp., Enterobacter spp.; (RTax_e4)). Our prediction models included at
most one taxonomic and one resistance metric, and evaluated six
resistance and taxonomy metric combinations in total. We refer to
these six combinations as taxonomy-adjusted AMR metrics.
2.7. Statistical analysis
For each of the six taxonomy-adjusted AMR metrics, we fitted a
Bayesian generalized linear model to the infection data and applied
Bayesian model comparison based on out-of-sample prediction accu-
racy. This allowed us to assess the potential of each metric to predict
antibiotic resistance amongst clinical invasive Enterobacterales iso-
lates and to determine the most predictive metric. Using cross-vali-
dation as a tool for model comparison penalizes models that are
overfitting the data. We used de-duplicated counts of isolates (unique
bacterial species per antibiogram and patient-ID) for the analyses. We
let i denote the setting (Cambodia, Kenya or UK), and j the antibiotic
being evaluated. We assumed that counts of resistant isolates follow
a binomial distribution. Our model then predicts the count of resis-
tance (ri,j) amongst tested Enterobacterales isolates (ni,j) using a prob-




¼ aj þ b1;jRCGC;i;j þ b2;jRTax;i ð1Þ
4 O.T. Auguet et al. / EClinicalMedicine 36 (2021) 100910We included only those antibiotics that had existing antibiotic
susceptibility test (AST) data in 2 of three settings; missing observa-
tions were excluded from the likelihood evaluation. Due to the lim-
ited number of infection isolates with AST results (especially in
Cambodia), we chose standard weakly informative priors for the
intercept (aj) and the effect parameters (b1,j, b2,j; appendix pp9-11).
In addition, we restricted the effect of AMR gene abundance to be
positive, reflecting our view that only a positive association of AMR
genes and clinical resistance is biologically reasonable. Each model
was fit using Stan software [21] (v2.19.1), taking 50,000 samples after
a burn-in period of 5000 samples using four independent chains. We
assessed chain convergence by inspecting chain traceplots and ensur-
ing small values of the R-hat chain convergence diagnostic (R-
hat<0.01) [22].
The best taxonomy-adjusted AMR metric was selected using
Bayesian leave-one-out cross validation [23], which estimates the
model’s pointwise out of sample prediction accuracy. Importantly,
as opposed to assessments of within sample prediction, leave-one
out cross-validation estimates how well a model is expected to
predict new, unseen data points, and it thus penalizes models
that are overfitting. In addition to the six model versions with
the different taxonomy-adjusted AMR metrics, we also included
in the comparison one baseline model with resistance metrics
(RCGC) but without taxonomy metrics (RTax), one with only taxon-
omy metrics (RTax), and a baseline (null) model with only inter-
cepts (keeping only aj). This was to assess the value of
considering only taxonomy or only AMR metrics (i.e. whichever
RTax or RCGC metric performed best in the models considering
combinations), against the value of combining these into a taxon-
omy-adjusted AMR metric for predicting clinical resistance. The
within sample fit of the best model (chosen based on cross-vali-
dation) and of the null model, was assessed using logarithmic
scoring of the posterior predictions against the observed counts
of resistant isolates. This type of scoring assigns low scores to
models with highly diffuse (uncertain) predictive distributions,
and also to narrow but wrongly placed distributions, and is
rooted in information theory and the definition of entropy [24].
For settings and antibiotics where zero samples were tested, we
imputed the sample size by computing the rounded mean of the
sample sizes of the other two settings. Model comparisons and
all further data analyses were performed in R-3.6.1 statistical
software [25].2.8. Ethical approvals
Ethical approval for faecal/rectal samples was already in place
(KEMRI/SERU/CGMR- C/023/3161, OXTREC 47-15 [26]; OxTREC ref
1047-13 [27]; and REC: 14/LO/2085 [28,29]). Samples were only col-
lected from patients who provided informed consent or, in the case
of children, whose parents/guardians provided consent on their
behalf. This study was approved by the Oxford Tropical Research
Ethics Committee (Reference: 5126-16), with additional local ethics
clearance for inclusion of Cambodian and Kenyan samples, and a sub-
stantial amendment to 14/LO/2085 (NRES London-Camberwell St
Giles) for UK samples.2.9. Role of funding source
The funders and sponsor of the study had no role in study design,
data collection, data analysis, data interpretation, or writing of the
report; the views expressed are those of the authors and not neces-
sarily those of the funders or the sponsor. All authors had full access
to all the data in the study and had final responsibility for the deci-
sion to submit for publication.3. Results
3.1. Metagenomic sequencing outputs
To enable efficient indexing, this study considered only samples
with DNA yields 1 ng/ul (7989% of hospital admission samples).
Population pools in Kenya, the UK and Cambodia therefore comprised
177, 157, and 156 pooled faecal sample extracts (Fig. 1). The total Gbp
of data per population pool was 51.6 (Kenya), 55.1 (UK) and 52.6
(Cambodia). The median Gbp for individually sequenced samples was
24.2 (Kenya), 22.1 (Cambodia) and 22.4 (UK). The following sections
report the results of the analysis of population pools. The results of
the validation of our pooling approach, which also consider metage-
nomic information from 30-sample pools and individual samples to
assess whether pooled metagenomes are a fair representation of the
individual metagenomes, are provided in the supplementary appen-
dix (pp 18-19).3.2. Taxonomic profiling of population metagenomes
Enterobacterales were the most abundant bacterial taxa identified
in the UK (75.7%) and Cambodia (69.7%) but not Kenyan (32.4%;
Fig. 2, panel 1A) population metagenomes, consistent with previous
Kenya data [30]. Amongst Enterobacterales, >95% abundance was
attributable to the Enterobacteriaceae family, across settings (UK:
96.3%; Cambodia: 99.4%; Kenya: 99.1%) (Fig. 2, panel 1A). The most
abundant Enterobacterales genera/species were E. coli and K. pneumo-
niae, followed by Enterobacter spp. (Fig. 2, panel 1B; 92.4% of all Enter-
obacterales taxa in Kenya, 88.5% in the UK, 88.1% in Cambodia). The
abundance of E. coli was >20-fold higher than that of K. pneumoniae
in UK (E. coli: 63.2%; K. pneumoniae: 2.2%) and Kenyan (E. coli: 28.4%;
K. pneumoniae: 1.3%) metagenomes, reflecting the fact that in general,
E. coli is thought to be a more dominant gastrointestinal coloniser
than K. pneumoniae. In contrast both species had similar abundance
in the Cambodian metagenome (E. coli: 30%; K. pneumoniae: 26.9%),
consistent with previous high rates of K. pneumoniae colonisation
identified on culture in the neonatal group studied [27]. Enterobacter
spp. abundance was also higher in Cambodia (4.5%) compared to the
UK (1.6%) or Kenya (0.2%). Other Enterobacterales genera represented
<2% of bacterial abundance across settings (appendix p12).3.3. Enterobacterales isolates causing bloodstream and cerebrospinal
infections
Amongst 197, 910 and 3356 bacterial isolates cultured from
blood/cerebrospinal fluid infections in Cambodia, Kenya and the UK,
respectively, infections by Enterobacterales accounted for approxi-
mately a third across settings (Kenya: 36.8%; Cambodia: 33.0%; UK:
28.2%) (Fig. 2, panel 2A). Similar to the population-pool metagenomic
data, most of these involved Enterobacteriaceae (UK: 91.2%, Cambo-
dia: 89.2%; Kenya: 91.8%; Fig. 2, panel 2A), and specifically E. coli and
K. pneumoniae, with higher proportions of E. coli infections in the UK
(E. coli: 16.1%; K. pneumoniae: 4.8%) and Kenya (E. coli: 13.8%; K. pneu-
moniae: 5.9%), versus Cambodia (E. coli: 13.7%; K. pneumoniae: 11.7%)
(Fig. 2, panel 2B). Enterobacter spp. was the next most common Enter-
obacterales genus causing infection across settings (Cambodia: 3.1%;
Kenya: 2.7%; UK: 2.2%), with other Enterobacterales genera account-
ing for <2% of the total invasive infections (appendix p13). A notable
exception was Salmonella spp., accounting for 9.9% of the total infec-
tions in Kenya (therefore included in Fig. 2, panels 1B, 2B), consistent
with data supporting the high rates of non-typhoidal salmonellosis
here [31].
Fig. 1. Overview of sample and data collection and study methods. The study collated human faecal material from existing biobanks in Kenya, UK and Cambodia. Collections comprised
210, 200 and 230 samples from Kenya (Apr-Sep 2016), UK (Feb-May 2015) and Cambodia (Sep 2013-Sep 2014), respectively. Following DNA extraction, samples with 1 ng/ml were
used to create a metagenomics population pool from each setting. Amongst these, 30 samples with  300 ng/34ml were randomly selected to also be individually sequenced and to
create a 30-sample pool, for a pooling validation study (see appendix pp11, 18-19). Each setting provided microbiology and AST results from hospital laboratory information sys-
tems (LIS), for blood and cerebrospinal fluid clinical samples collected on admission to the same hospitals over a seven-year period (20102017). DNA samples were sequenced
using HiSeq 4000 Illumina platform; 150 bp paired-end reads were quality-filtered using a recently developed bioinformatics pipeline [15]. Sequences were mapped against NCBI
for profiling the abundance of bacterial species, and against the Comprehensive Antibiotic Resistance Database (CARD) [18,19] for profiling antimicrobial resistance (AMR) genes/
variants. The number of sequences that mapped to each AMR gene were corrected to remove resistance gene length bias, by computing corrected gene counts (CGCs). The CGCs
were then aggregated according to the antibiotic these conferred resistance to. Several combinations of resistance (RCGC) and taxonomy (RTax) abundance metrics were considered
in a Bayesian modelling analysis, to assess the potential of each metric to predict antibiotic resistance amongst clinical invasive Enterobacterales isolates observed from LIS data in
the three settings.
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Fig. 2. Major Enterobacterales in metagenomic population pools and in bloodstream and cerebrospinal fluid infections. The figure shows relative abundances of Enterobacterales in meta-
genomic population pools and proportions of blood and cerebrospinal fluid infections caused by major Enterobacterales in Cambodian, Kenyan and UK study settings. Panels for
metagenomic population pools (1A, 1B) show, for each setting, the abundances of Enterobacterales taxa divided by the total abundance of bacterial taxa in a pool. Abundances are
derived from Bracken estimates. Panels for invasive infection data (2A, 2B) show the proportion of bloodstream and cerebrospinal fluid isolates that were Enterobacterales out of all
bloodstream and cerebrospinal fluid isolates with speciation results in target age groups, in each setting, from 2010 to 2017 (Cambodia [n = 197]; Kenya [n = 910]; UK [n = 3356]).
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We identified 863 different AMR genes across all samples/
pools, including those known to confer clinically-relevant resis-
tance for 113 antimicrobials (AMRDEF) and to increase the MIC for
163 antimicrobials (AMRALL). A specific evaluation of AMR gene
richness, on rarefied data (appendix p9), demonstrated that the
number of AMR genes in population pools and individual samples
differed by geographical setting, being highest in Cambodia
(appendix p18).
In the population metagenomes, the highest relative AMR gene
abundances were for those associated with resistance to aminoglyco-
sides, amphenicols, fluoroquinolones, tetracyclines and macrolides
(48.1%, 45.8% and 43.6% of total AMR gene counts in Cambodia, Kenya
and the UK, respectively) (Fig. 3, left-hand panel). However, the rela-
tive abundance of these differed between settings. For example, the
relative abundance of AMR genes for aminoglycosides in Cambodia
(18.4%) was almost double that in Kenya (10.8%) or the UK (10.9%).
The next highest relative abundance was of genes conferring resis-
tance to penicillins (Cambodia: 4.1%; Kenya: 4.7%; UK: 5.0%) andcephalosporins (Cambodia: 2.6%; Kenya: 2.3%; UK: 2.2%). AMR gene
counts for other antibiotic classes were <2% of the total gene counts
across settings, including to carbapenems (Kenya [0.5%], Cambodia
and the UK [0.4%]). For single antibiotics or antibiotic sub-classes (e.g.
1st generation cephalosporins), the highest relative abundances were
observed for erythromycin (Cambodia: 3.9%; Kenya: 4.2%; UK: 4.4%)
and chloramphenicol (Cambodia: 3.6%; Kenya: 3.5%; UK: 4.2%) in all
settings (Fig. 3, right-hand panel).3.5. Susceptibility phenotypes of Enterobacterales isolates causing
bloodstream and cerebrospinal infections
Phenotypic resistance in Enterobacterales isolates causing blood
and cerebrospinal fluid infections was analysed for 16 antibiotics
with antibiotic susceptibility test (AST) data in 2 study settings
(Fig. 4). In Cambodia, resistance prevalence >30% was observed for
all antibiotics except nitrofurantoin (not used to treat bloodstream or
cerebrospinal fluid infections) and carbapenems; less phenotypic
resistance was seen in isolates from Kenya and the UK (Fig. 4).
Fig. 3. Relative abundance of AMR genes (corrected gene counts [CGCs]) in metagenomic population pools. Panels show, for each setting, corrected resistance gene counts (CGCs) for
major antibiotic classes (left-hand panel), or antibiotic sub-classes/types (right-hand panel), divided by the total corrected AMR gene counts identified in the population pool. Rela-
tive abundances were calculated using RCGC_ALL, which considers corrected counts of genes and variants (CGC) increasing the MIC or conferring clinically relevant resistance for a
given antibiotic. “Trim-sulfa” is trimethoprim-sulfamethoxazole; <number>G denotes the generation of cephalosporin (e.g. 1G represents first generation cephalosporins).
O.T. Auguet et al. / EClinicalMedicine 36 (2021) 100910 73.6. Modelling the prevalence of AMR in clinical infections from pooled
faecal metagenomic data
The best taxonomy-adjusted AMR metric (resulting in the highest
point-wise out of sample prediction accuracy based on cross-valida-
tion) used the taxonomic metric RTax_e4 measuring the commonest
Enterobacterales species in clinical isolates (Escherichia coli, Klebsiella
pneumoniae, Salmonella spp., Enterobacter spp.), and the abundance
of AMR genes increasing the MIC or conferring clinically relevant
resistance (RCGC_ALL). The model considering both RTax_e4 and RCGC_ALL
as predictors outperformed other models in terms of out-of-sample
predictions (Fig. 5). Models considering only AMR abundance
(RCGC_ALL), or only taxonomic information (RTax_e4) only marginally
improved predictions relative to a baseline (null) model without any
metagenomic information, whilst models with combined RCGC and
RTax showed substantially improved performance (difference in leave
one out cross-validation log predictive densities compared to best
model: Null [no RCGC and no RTax] = 223 [330,116]; Baseline
[RCGC_ALL only] = 186 [281,91]; Baseline [RTax_e4 only] = 151
[232,69]; appendix p14). Thus, we expect our best modelconsidering both RTax_e4 and RCGC_ALL, to make substantially improved
predictions compared to models with only one metric or no metage-
nomic metrics.
We compare the fits of the different models using logarithmic
scoring, where a higher score indicates a better fit. The best model
(RTax_e4 and RCGC_ALL) had a score of 133 (95% credible interval:
143, 123) and the null model a score of 298 (95% CI 304,
292). As a means to visualise the predictions of our best model, pre-
dictions were made for the 16 antibiotics with AST data in 2 settings
for Enterobacterales isolates causing infection and then plotted
against the observed resistant counts (Fig. 6). Predictions from the
best model and those from the baseline (null) model are also pre-
sented in a table alongside the observed resistant counts for compari-
son purposes (appendix pp15-16). The mean-squared errors of the
mean model predictions relative to the observations showed that the
null model had an error of 468 compared to the best model, which
had an error of 33. Bayesian model predictions expressed as percen-
tages instead of counts are shown in appendix p17 for antibiotics
with AST results from >100 invasive infection isolates (i.e. 14 antibi-
otics in the UK and/or Kenya).
Fig. 4. Phenotypic resistance observed in Enterobacterales isolates causing bloodstream and cerebrospinal fluid infection in study settings. Results are displayed for 16 antibiotics with
susceptibility data across  2 settings from 2010 to 2017. Percentages are shown with 95% exact binomial confidence intervals (CI). “Trim-sulfa” is trimethoprim-sulfamethoxazole.
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In this exploratory study we suggest that metagenomic analysis of
pooled extracts from individual faecal samples could be effective at
predicting resistance in invasive Enterobacterales infections fromdifferent age groups and geographic settings at the population-level,
if both AMR gene abundances and taxonomy metrics from the pooled
metagenomes are considered. Our approach would enable intermit-
tent, relatively non-invasive sampling of a small subset of individuals
within a population (e.g. 100200), with a single centralised
Fig. 5. Bayesian model comparison using leave-one-out cross-validation. The leave-one-out prediction accuracy is shown on the x-axis measured as expected log pointwise predictive
density [23] (elpd_loo) compared to the best performing model. The points show mean estimates and horizontal bars two times the standard error. The models are ordered from
top to bottom by their mean elpd_loo difference to the best model. The best model is the model using RTax_e4 and RCGC_ALL.
O.T. Auguet et al. / EClinicalMedicine 36 (2021) 100910 9infrastructure (either in-country or internationally) undertaking
metagenomic sequencing, analysis and prediction of population-level
AMR in clinical Enterobacterales isolates. Although this could be done
in parallel with the local development of microbiology laboratory
networks, our approach would not be dependant on consistent sam-
pling of individuals with infection. Our findings are supported by
other studies successfully using sewage for global AMR surveillance
and prediction of AMR in clinical isolates [810], but our approach
could be more feasible in many LMIC settings where wastewater
treatment/sewage infrastructures are scarce, and sewage sampling
would therefore not be feasible. Population-level sampling could also
overcome some of the potential biases affecting AMR prevalence esti-
mates if only unwell individuals presenting to tertiary referral
centres are sampled.
Based on pool size and sequencing depth (5055 Gbp/pool), we
avoided the need for potentially more expensive and labour-inten-
sive individual indexing of DNA extracts in a pool, or the issues asso-
ciated with targeted sequencing based on predefined AMR gene
panels. Our strategy also enabled us to include samples with low
DNA yields which may otherwise have failed library preparation;
exclusion of these samples could potentially introduce bias. Uniquely,
our bioinformatics pipeline incorporates the capacity to identify both
specific AMR gene variants (e.g. blaCTX-M-33 versus blaCTX-M-63) alongside
being able to aggregate by gene family. This is especially important as
genes that differ by only single nucleotides/amino acids can have distinct
phenotypic spectra. Although further validation of sample sizing and
pooling strategies are needed, population pools comprising rectal swabs
with as little as 1 ng/ul DNA/sample appeared to be sufficient to dem-
onstrate predictive value in this proof-of-principle study.Limitations of our approach were most obvious for the Cambodian
setting, where observed resistance values from invasive isolates were
within the 95% credible intervals of the best model predictions for
only 75% of antibiotics. One explanation might be that the population
pool erroneously included 19 additional longitudinal samples (12% of
all samples in the pool) collected from neonates after hospitalisation,
potentially compromising the analysis designed to reflect commu-
nity-associated profiles (rapid changes occur in the neonatal resis-
tome following hospitalisation/antibiotic exposures [32], and so this
group may need more regular metagenomic sampling to accurately
capture more rapid microbiome/resistome shifts). Cambodia was also
the only setting where the age group in the metagenomics analysis
(i.e. neonates), did not correspond exactly with the infection meta-
data analysed (i.e. infants 90 days of age). Clinical AST data in this
setting were also scarce; the maximum number of isolates with AST
results for any antibiotic was 65, compared to 324 in Kenya and 912
in UK. Ideally AST approaches would have been standardised across
the settings. Finally, our analyses are heavily dependant on the accu-
racy of genotypic-phenotypic associations in the reference AMR gene
catalogue. In general, however, we would expect this knowledge
base to become increasingly robust, thus strengthening predictions.
Our approach cannot be used for individual-level predictions; the
value of accurate and rapid infectious diseases diagnostics in the
management of individual patients remains clear.
Notwithstanding these limitations, we were able to predict AMR
in clinical Enterobacterales isolates at the population-level using mod-
els that included AMR gene abundances and taxonomy metrics from
the pooled faecal metagenomes, in three distinct geographic settings
and age groups, in this exploratory study. We used a cross-validation
Fig. 6. Bayesian model prediction of resistant Enterobacterales bloodstream and cerebrospinal fluid infections in study settings. Only antibiotics with antibiotic susceptibility test (AST)
results in 2 settings are considered. Horizontal bars represent 95% highest density posterior interval and vertical lines represent means of the predicted resistant sample counts
based on the model using metagenomic data from population pools. Coloured bars are shown where clinical data on resistance (i.e. AST) was available and grey bars where it was
not. For grey bars the sample size was imputed. Red circles show the number of blood and cerebrospinal fluid Enterobacterales infections that were found to be resistant to the anti-
biotic listed in the y-axis. The number of isolates with AST results for each antibiotic are also given on the y-axis. Red circles are missing where no AST results were available. In cases
where there is minimal uncertainty in the model estimate, the red circle may overshadow the 95% credible interval bars (e.g. meropenem [Cambodia]; cefuroxime [Kenya]). “Trim-
sulfa” is short for trimethoprim-sulfamethoxazole; “Cloramph” is short for chloramphenicol. NT = no AST data available (For interpretation of the references to color in this figure
legend, the reader is referred to the web version of this article.).
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O.T. Auguet et al. / EClinicalMedicine 36 (2021) 100910 11approach to compare the prediction accuracy of the different models.
It is notable that although no setting-specific parameters were
included in the models, predictions from the best model in most
cases showed good agreement with observed counts of resistant
infections in each setting. Further studies to validate these promising
proof-of-principle observations in additional settings across age cate-
gories, regions and in community versus healthcare-associated con-
texts, are warranted. There is potential to extend the approach to
other priority bacteria and different colonisation samples. Future
studies should also consider additional methodological simplification
such as pooling all samples prior to DNA extraction. A mathematical
framework for minimum-cost implementation of pooled-sample
metagenomics-based surveys to quantify the burden of AMR in new
settings without prior microbiology or AST data would also be of ben-
efit, and could be greatly informed by the data we have generated.
Surveillance based on population colonisation metagenomics and
taxonomy-adjusted AMRmetrics presented here is a potentially valu-
able public health opportunity. This approach could theoretically be
used to rapidly overcome the current paucity of quality AMR surveil-
lance data and inform setting and population-tailored rationalization
of empirical antibiotic use and treatment guidelines, develop meas-
ures to prevent and/or mitigate AMR, and ultimately improve public-
health decision-making in conjunction with relevant stakeholders,
especially in LMICs.
Data sharing
The raw sequence data reported in this study have been deposited
in the European Nucleotide Archive under accession number
PRJEB34871. The code to extract CARD data, including relationship
ontology terms that were required to generate the final datasets, plus
any required input files, are available from the ResPipe GitLab reposi-
tory (https://gitlab.com/hsgweon/ResPipe). This includes all com-
mands and parameters run for with TrimGalore, Kraken2, Bracken,
BBPMAP and ResPipe (the bioinformatics pipeline). The curated anal-
ysis datasets (Corrected gene counts; AMR_DEF; AMR_ALL; dataset for
Bayesian analysis) can be found at https://data.mendeley.com/data
sets/sxn6sw4r57/1 (Mendeley Data, V1, doi: 10.17632/
sxn6sw4r57.1) along with the R code used to produce these and the
code to run the Bayesian analysis.
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